|
Congestive heart failure (congestive heart failure, CHF) to heart failure, neurohormonal activation and abnormal distribution of blood flow is characterized by complex clinical syndrome, sympathetic enhanced renin - angiotensin - aldosterone system is activation, manifested as increased blood pressure, heart rate, respiratory rate increases and breathing difficulties and other clinical features, cause of death was cardiovascular disease the most important reason. BNP (brain natriuretic peptide, BNP) in 1988 from a purified porcine brain natriuretic peptide, ventricular cells in the ventricular pressure overload or volume overload increased secretion when the ventricular wall tension changes in load and BNP synthesis is stimulated and secretion of the main factors, with the expansion of blood vessels, natriuretic and diuretic effects. In recent years, BNP in heart failure diagnosis, treatment and prognostic value of growing concern. Numerous studies have confirmed that in the early asymptomatic heart failure, BNP levels that are elevated BNP levels in patients while CIHF significantly higher than normal; BNP mechanism of action is through the vessel wall NPR-A receptor binding , activation of guanylate cyclase, increased intracellular cyclic guanosine monophosphate levels, causing vascular smooth muscle relaxation, 2005 European Society of Cardiology its inclusion of CHF treatment guidelines. Objective: This study shows that the application of recombinant human brain natriuretic peptide (rhBNP) can significantly improve the treatment of heart failure patients with heart failure patients neurohormonal activation, its diuretic natriuretic effect, vasodilation, inhibition of the activity of aldosterone and renin secretion in the regulation fluid volume, blood pressure and electrolyte balance plays an important role in heart failure patients can achieve improved clinical symptoms, improve the body norepinephrine, endothelin, vasopressin, and BNP levels, thereby preventing the development of heart failure, reverse the vicious cycle of development of heart failure, to improve heart failure, to relieve symptoms and improve survival and improve the prognosis results. Methods: Inclusion criteria NYNH cardiac function grade Ⅲ and above 100 patients randomized experimental group of 50 patients in the control group of 50 patients, the symptoms observed in patients before treatment, after treatment, and one week after treatment in plasma BNP, go norepinephrine, endothelin, vasopressin changes. Enzyme-linked immunosorbent assay samples BNP, norepinephrine, endothelin, vasopressin levels and compare the treatment group and sodium nitroprusside rhBNP treatment group before and after treatment of the factor changes. Exclusion criteria: acute myocardial infarction, atrial fibrillation, primary pulmonary hypertension, right ventricular dysfunction, acute and chronic infections, sepsis, cancer, plasma creatinine concentration gt; 201 umol / L, end-stage renal disease, cirrhosis , primary aldosteronism, chronic obstructive pulmonary disease, adult respiratory distress syndrome, Cushing syndrome, hyperthyroidism. Results rhBNP group and sodium nitroprusside group improvement of cardiac function after treatment was statistically significant (P lt; 0.05), two plasma BNP, norepinephrine, endothelin, vasopressin levels were decreased, which BNP , norepinephrine, endothelin compared with before treatment had significant difference (P lt; 0.01), the experimental group BNP, norepinephrine levels compared with the control group, the difference was statistically significant (P lt; 0.05). Conclusion rhBNP treatment of severe heart failure patients, can significantly improve patients' ventricular systolic and diastolic function, increased cardiac output, delay ventricular remodeling is a safe and effective drug treatment of CHF.
|